843 Intra-cerebral spinal fluid vaccination to facilitate antigen-specific T-cell responses in the CNS tumors

Background

Immunotherapies such as immune checkpoint inhibitors and CAR-T therapies have revolutionized cancer treatment in recent years. However, the success of the immunotherapies has been only limited to a small percentage of patients as primary and secondary resistance to single agent remains common and often results in treatment failure. Combination immunotherapies (e.g. combining multiple immune targets or different therapeutic modalities) have become a potential strategy to combat this drug resistance.

Methods

Here we describe a 3D in vitro tumor model platform which can be used for assaying anti-tumor effects of novel immunotherapy combinations. The models incorporate tumor cells derived from patient-derived xenografts, fibroblasts and immune cells in a hydrogel matrix to recreate the complex TME. Tumor size reduction and tumor cell death were determined as endpoint readouts via high content imaging.¹ The 96-well high-throughput format allows rapid screening for novel combinations and their additive or synergistic effects across multiple PDX types.

Results

As a proof of concept, we tested the combination of anti-CTLA4 (Ipilimumab) and anti-PD1 (Nivolumab), both FDA approved treatments, to showcase their enhancement effect in several PDX models.² We also observed that dosing kinetics and immune cell density dictated the degree of response for each agent compared to their combination.

Conclusions

The Cypre 3D platform is a broadly encompassing tool capable of exploring novel combinations that alter multiple mechanisms of immune response.

References

Xue B, Schüler J, Harrod CM, Lashuk K, Bomya Z, Hribar KC. A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies. Cells. 2023;12:1–14. Larkin J, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New Engl J Med. 2019;381:1535–1546.